卒中患者中的2型糖尿病：对法国预后、复发、资源使用和成本的影响

IF 5.8 3区医学 Q1 CLINICAL NEUROLOGY

European Stroke Journal Pub Date : 2025-02-14 DOI:10.1177/23969873251319172

Igor Sibon, Kamel Mohammedi, Nadia Quignot, Stephanie Read, Raissa Kapnang, Artak Khachatryan, Kazue Kikuchi, Hongye Ren, Christine Massien, Lucile Vigié, Sara Larsen, Laurent Fauchier

{"title":"卒中患者中的2型糖尿病：对法国预后、复发、资源使用和成本的影响","authors":"Igor Sibon, Kamel Mohammedi, Nadia Quignot, Stephanie Read, Raissa Kapnang, Artak Khachatryan, Kazue Kikuchi, Hongye Ren, Christine Massien, Lucile Vigié, Sara Larsen, Laurent Fauchier","doi":"10.1177/23969873251319172","DOIUrl":null,"url":null,"abstract":"Introduction: Contemporary estimates of the impact of type 2 diabetes (T2D) on stroke outcomes are important for care planning and resource allocation. This retrospective cohort study compared the incidence of stroke and subsequent clinical and economic outcomes following stroke among people with and without T2D.Patients and methods: Data were extracted from a subset of the French Système National des Données de Santé database. Stroke incidence as well as post-stroke clinical outcomes, healthcare resource utilization (HCRU), use of stroke preventative treatments, and costs were compared among people with and without T2D.Results: The study included 10,906 patients hospitalized for stroke including 2141 (19.6%) people with T2D. Age-standardized stroke incidence rates were 3.3 (95% confidence interval [CI] 3.1; 3.6) per 1000 person-years and 2.2 (2.1; 2.3) in people with and without T2D, respectively. Patients with T2D had significantly higher risk of stroke recurrence (adjusted hazard ratio [HR] 1.14, 95% CI: 1.01; 1.30) and mortality (HR 1.16, 95% CI: 1.08; 1.25) than patients without T2D. The proportion of patients with T2D treated with statins decreased from 27.3% pre-stroke to 20.6% post-stroke but remained relatively stable among patients without T2D (from 13.4% to 13.1%). The mean healthcare costs in the 12 months following stroke were higher among patients with T2D than those without (€22,635 vs €18,629).Discussion and conclusion: The incidence and clinical and economic burden of stroke is considerably higher among people with T2D. Further efforts are needed to reduce this disparity.","PeriodicalId":46821,"journal":{"name":"European Stroke Journal","volume":" ","pages":"23969873251319172"},"PeriodicalIF":5.8000,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829279/pdf/","citationCount":"0","resultStr":"{\"title\":\"Type 2 diabetes in stroke patients: Impact on outcomes, recurrence, resource use, and costs in France.\",\"authors\":\"Igor Sibon, Kamel Mohammedi, Nadia Quignot, Stephanie Read, Raissa Kapnang, Artak Khachatryan, Kazue Kikuchi, Hongye Ren, Christine Massien, Lucile Vigié, Sara Larsen, Laurent Fauchier\",\"doi\":\"10.1177/23969873251319172\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Contemporary estimates of the impact of type 2 diabetes (T2D) on stroke outcomes are important for care planning and resource allocation. This retrospective cohort study compared the incidence of stroke and subsequent clinical and economic outcomes following stroke among people with and without T2D.Patients and methods: Data were extracted from a subset of the French Système National des Données de Santé database. Stroke incidence as well as post-stroke clinical outcomes, healthcare resource utilization (HCRU), use of stroke preventative treatments, and costs were compared among people with and without T2D.Results: The study included 10,906 patients hospitalized for stroke including 2141 (19.6%) people with T2D. Age-standardized stroke incidence rates were 3.3 (95% confidence interval [CI] 3.1; 3.6) per 1000 person-years and 2.2 (2.1; 2.3) in people with and without T2D, respectively. Patients with T2D had significantly higher risk of stroke recurrence (adjusted hazard ratio [HR] 1.14, 95% CI: 1.01; 1.30) and mortality (HR 1.16, 95% CI: 1.08; 1.25) than patients without T2D. The proportion of patients with T2D treated with statins decreased from 27.3% pre-stroke to 20.6% post-stroke but remained relatively stable among patients without T2D (from 13.4% to 13.1%). The mean healthcare costs in the 12 months following stroke were higher among patients with T2D than those without (€22,635 vs €18,629).Discussion and conclusion: The incidence and clinical and economic burden of stroke is considerably higher among people with T2D. Further efforts are needed to reduce this disparity.\",\"PeriodicalId\":46821,\"journal\":{\"name\":\"European Stroke Journal\",\"volume\":\" \",\"pages\":\"23969873251319172\"},\"PeriodicalIF\":5.8000,\"publicationDate\":\"2025-02-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829279/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Stroke Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/23969873251319172\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Stroke Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/23969873251319172","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

当代2型糖尿病（T2D）对卒中预后影响的评估对护理计划和资源分配很重要。这项回顾性队列研究比较了有和没有T2D的人群卒中发生率以及卒中后的临床和经济结果。患者和方法：数据提取自法国系统国家des donnsam数据库的一个子集。比较t2dm患者和非t2dm患者的卒中发生率、卒中后临床结果、医疗资源利用率（HCRU）、卒中预防治疗的使用和费用。结果：该研究纳入10,906例卒中住院患者，其中2141例（19.6%）为t2dm患者。年龄标准化脑卒中发病率为3.3(95%可信区间[CI] 3.1；3.6) / 1000人年和2.2 (2.1；2.3) t2dm患者和非t2dm患者的差异。t2dm患者卒中复发风险明显增高(校正危险比[HR] 1.14, 95% CI: 1.01；1.30)和死亡率(HR 1.16, 95% CI: 1.08；1.25)高于无T2D患者。接受他汀类药物治疗的T2D患者比例从卒中前的27.3%下降到卒中后的20.6%，但在没有T2D的患者中保持相对稳定（从13.4%降至13.1%）。T2D患者中风后12个月内的平均医疗费用高于非T2D患者（22,635欧元对18,629欧元）。讨论与结论：T2D患者卒中的发病率、临床和经济负担都要高得多。需要进一步努力缩小这种差距。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Type 2 diabetes in stroke patients: Impact on outcomes, recurrence, resource use, and costs in France.

Introduction: Contemporary estimates of the impact of type 2 diabetes (T2D) on stroke outcomes are important for care planning and resource allocation. This retrospective cohort study compared the incidence of stroke and subsequent clinical and economic outcomes following stroke among people with and without T2D.

Patients and methods: Data were extracted from a subset of the French Système National des Données de Santé database. Stroke incidence as well as post-stroke clinical outcomes, healthcare resource utilization (HCRU), use of stroke preventative treatments, and costs were compared among people with and without T2D.

Results: The study included 10,906 patients hospitalized for stroke including 2141 (19.6%) people with T2D. Age-standardized stroke incidence rates were 3.3 (95% confidence interval [CI] 3.1; 3.6) per 1000 person-years and 2.2 (2.1; 2.3) in people with and without T2D, respectively. Patients with T2D had significantly higher risk of stroke recurrence (adjusted hazard ratio [HR] 1.14, 95% CI: 1.01; 1.30) and mortality (HR 1.16, 95% CI: 1.08; 1.25) than patients without T2D. The proportion of patients with T2D treated with statins decreased from 27.3% pre-stroke to 20.6% post-stroke but remained relatively stable among patients without T2D (from 13.4% to 13.1%). The mean healthcare costs in the 12 months following stroke were higher among patients with T2D than those without (€22,635 vs €18,629).

Discussion and conclusion: The incidence and clinical and economic burden of stroke is considerably higher among people with T2D. Further efforts are needed to reduce this disparity.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Stroke Journal Multiple-

CiteScore

7.50

自引率

6.60%

发文量

102

期刊介绍： Launched in 2016 the European Stroke Journal (ESJ) is the official journal of the European Stroke Organisation (ESO), a professional non-profit organization with over 1,400 individual members, and affiliations to numerous related national and international societies. ESJ covers clinical stroke research from all fields, including clinical trials, epidemiology, primary and secondary prevention, diagnosis, acute and post-acute management, guidelines, translation of experimental findings into clinical practice, rehabilitation, organisation of stroke care, and societal impact. It is open to authors from all relevant medical and health professions. Article types include review articles, original research, protocols, guidelines, editorials and letters to the Editor. Through ESJ, authors and researchers have gained a new platform for the rapid and professional publication of peer reviewed scientific material of the highest standards; publication in ESJ is highly competitive. The journal and its editorial team has developed excellent cooperation with sister organisations such as the World Stroke Organisation and the International Journal of Stroke, and the American Heart Organization/American Stroke Association and the journal Stroke. ESJ is fully peer-reviewed and is a member of the Committee on Publication Ethics (COPE). Issues are published 4 times a year (March, June, September and December) and articles are published OnlineFirst prior to issue publication.